Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

Renal Insufficiency, Chronic Clinical Trial

— MRC-Gard  

Official title:

Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02938611
• Other study ID #: NIMAO/2016-06/OM-01
• Status: Recruiting
• Start date: January 1, 2019
• Est. completion date: December 2025

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: Olivier Moranne, MD, PhD
• Phone: +33.(0)4.66.68.31.49
• Email: olivier.moranne[@]chu-nimes.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3375
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• chronic kidney disease (stage >= 4) Exclusion Criteria: -

Related Conditions & MeSH terms

• Renal Insufficiency
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
France	AIDER - Unité de Dialyse d'Alès	Alès
France	Gardialyse	Nîmes
France	AIDER - Unité de Dialyse de Nîmes, CHU Carémeau	Nîmes Cedex 09
France	CHU de Nîmes - Hôpital Universitaire Carémeau	Nîmes Cedex 09

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)		from baseline (day 0) to 12 months
Primary	The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)		from baseline (day 0) to 12 months
Secondary	The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists		from baseline (day 0) to 12 months
Secondary	For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared		from baseline (day 0) to 12 months
Secondary	The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist		from baseline (day 0) to 12 months